SOLICITATION NOTICE
65 -- Services to expand, titer and aliquot virus stocks: Modified Vaccinia Virus Ankara (MVA) Agagpolenv and MTV retanef, for AIDS vaccine research
- Notice Date
- 5/13/2010
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100084-AV
- Archive Date
- 6/12/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 634A, Rockville, MD 20852, UNITED STATES. The National Cancer Institute (NCI), Center for Cancer Research (CCR), Vaccine Branch (VB), plans to procure on a sole source basis with Advanced Biosciences Laboratories; 5510 Nicholson Lane; Kensington, MD 20895 to expand, titer and aliquot both virus stocks, Modified Vaccinia Virus Ankara (MVA) Agagpolenv and MTV retanef, for AIDS vaccine research. The North American Industry Classification System Code (NAICS) for this procurement is 325414 and the business size standard is 500 employees. This acquisition will be processing in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for one month. Poxvirus based HIV vaccine candidates are currently under evaluation in preclinical and clinical trials. Modified Vaccinia Virus Ankara (MVA) vectors are widely considered as the vaccinia virus strain of choice for clinical investigation because of its high safety profile, and excellent immunogenicity records. The recent study completed by the NCI demonstrated that mucosal immunization of macaques with a regimen including an SIV peptide vaccine adjuvanted with TLR 2/3/9 agonists and IL-15 to prime followed by 2 doses of MVA-SIV to boost could effectively protect more than 50% of the vaccinated animals against SIVmac251 challenge. Therefore, for future HIV vaccine development, and comparability of results with previous studies, the NCI proposes the continued use of MVA-SIV in the new regimen. Specifically, the contractor shall provide two strains of MVA-SIV, a total of 1011 pfu of each, which should also have the same quality as the MVA-SIV previously provided, so the lab can compare the results with the previous cohort. One strain should express SIV-gag, pol, env, and the other SIV-Rev, Tat, and Nef. The NCI does not know of another source to provide the specific recombinant MVA. Most importantly, the source must be an exact match of the batch of MVA used in previous studies. For these reasons, no other source is known to the NCI to provide the services or virus stocks required to complete the mission of the laboratory. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on May 28, 2010. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Ashley Virts, Contract Specialist, at virtsa@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100084-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100084-AV/listing.html)
- Record
- SN02149327-W 20100515/100513235634-02b5b99c80b6760b550c9f71ad8a463b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |